Please Wait...

Luc Bracoud

Translation skills

Main profile

Luc Bracoud, MSc
Director, Neuroscience

Luc Bracoud graduated from Ecole Centrale Lyon in 2001. He joined Theralys in 2002, which was later acquired by BioClinica (formerly known as Bio-Imaging Technologies) as a software developer and medical image processing engineer. He also served as a project manager, and has been involved in various large multi-center clinical trials mainly in Stroke, MS and AD, as well as Gaucher Disease. His main image processing activities are related to spatial registration, segmentation, atrophy quantification, perfusion imaging, diffusion and diffusion tensor imaging.

Authored Publications

Serge Gauthier, MD, Howard H Feldman, MD, Lon S Schneider, MD, Gordon K Wilcock, DM, Giovanni B Frisoni, MD, Jiri H Hardlund, MD, Hans J Moebius, MD, Peter Bentham, MBChB, Karin A Kook, PhD, Damon J Wischik, PhD, Bjoern O Schelter, Charles S Davis, PhD, Roger T Staff, PhD, Luc Bracoud, MSc, Kohkan Shamsi, MD, John M D Storey, Charles R Harrington, PhD, Claude M Wischik, MBBS.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. 15 November 2016. DOI: http://dx.doi.org/10.1016/S0140-6736(16)31275-2.

Coric V, Salloway S, H. van Dyck C, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targetting Prodromal Alzheimer Disease with Avagacestat A Randomized Clinical Trial.  JAMA Neurol 2015, Sept 28. [Epub ahead of print]

Sibon I, Tourdias T, Felix S, Asselineau J, Bracoud L, Vivot A, Rouanet F, Renou P, Orgogozo JM, Dousset V. Magnetisation transfer parameters and stroke outcome. J Clin Neurosci. 2015 Jun;22(6):1012-7.

Kufner A, Wouters A, Bracoud L, Laage R, Schneider A, Schäbitz W, Hermier M, Thijs V, Fiebach JB, on behalf of the AXIS2 investigators.  Infarct Volume-Based Subgroup Selection in Acute Ischemic Stroke Trials. Stroke, May 2015.

Opherk C, Gonik M, Duering M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, Liem M, Boon EM, Pescini F, Pachai C, Bracoud L, Müller-Myhsok B, Meitinger T, Rost N, Pantoni L, Oberstein SL, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Rosand J, Chabriat H, Dichgans M. Genome-Wide Genotyping Demonstrates a Polygenic Risk Score Associated With White Matter Hyperintensity Volume in CADASIL. Stroke. 2014 Feb 27. [Epub ahead of print]

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Clinical #datamanagement is essential to ensure high-quality data in #clinicaltrials, but the components are comple… https://t.co/klK81O6YA2
Bioclinica (18 hours ago)
Congratulations to Jeff Heilbraun, M.S., VP, Medical & Scientific Affairs, for his latest article on cardiovascular… https://t.co/JSuEaeQOYh
Bioclinica (5 days ago)
Changes are a fact of life - and of #clinicaltrial design. But planning and budgeting for your trial don’t have to… https://t.co/wsfMPAwLxR
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/dYDJO4Qh7S
Bioclinica (3 weeks ago)
Our webinar on Neuroimaging in Parkinson’s Disease is tomorrow at 10:30 a.m. EDT. Register at:… https://t.co/4j0FGeXG0B
Bioclinica (3 weeks ago)
Today is World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all female cancers. #Bioclinica p… https://t.co/1nMGahTMaz
Bioclinica (4 weeks ago)